Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-22

Clinical Trial Update: Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase II trial of bevacizumab in myelofibrosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)

Snippet

Sponsor: Ronald Hoffman | Conditions: Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2014-08-22